What clinical trials have tested Manuka honey for blood glucose control in humans?
Executive summary
Clinical human research directly testing Manuka honey’s effects on blood glucose is limited: the most specific controlled human trial measured the glycaemic index (GI) of several Manuka honeys in healthy volunteers and found moderate GI values (54–59) [1]. Broader clinical literature on “honey” suggests possible modest effects on fasting glucose, insulin and metabolic markers, but many trials pooled different honey types and sample sizes were small, so claims that Manuka honey meaningfully controls blood glucose in people with diabetes remain unproven [2] [3].
1. The clearest controlled human trial: Manuka’s glycaemic index in healthy volunteers
A randomized, crossover clinical trial that fed participants 25 g available carbohydrate from five Manuka honey samples and compared incremental blood‑glucose responses to a glucose reference found the five Manuka honeys produced moderate GI values (54–59), with peak glucose at ~30 minutes; the study is registered as NCT01615588 and reported the moderate GI outcome across those healthy volunteers [1] [4].
2. Small, varied human trials and observational signals — modest glycaemic and insulin changes reported
Reviews and secondary sources summarize multiple clinical trials of honey (not always Manuka‑specific) that observed effects on plasma glucose, insulin and lipids, and one 8‑week clinical trial that substituted honey for table sugar reported a ~4% drop in fasting blood glucose and modest weight change in the honey group versus sugar, but those results mix honey types and dietary contexts and cannot be taken as definitive evidence for Manuka alone [2] [3].
3. Very small or unusual human experiments that get cited but have limits
A small study of 16 healthy individuals exposed to aerosolized honey reportedly showed a 22% mean fall in blood glucose after 30 minutes and increased insulin, but the method (aerosolized delivery) and tiny sample constrain applicability to dietary Manuka honey use and diabetes care [5]. Another cited human report claimed honey raised C‑peptide in type 1 diabetes participants, implying beta‑cell stimulation, but the context and sample sizes referenced in promotional sources are not detailed enough in the available reporting to confirm reproducible clinical benefit [6].
4. Preclinical animal data suggest mechanisms but cannot substitute for human trials
Rodent experiments using Manuka honey or honey preparations show pancreatic histology changes, reductions in hyperglycaemia and modulation of transcription factors in induced‑diabetes models, supporting biological plausibility through antioxidant, anti‑inflammatory and enzyme‑inhibiting pathways—but these are animal studies and do not establish clinical efficacy or safe dosing in humans [7].
5. Quality, consistency and conflicts: why the human evidence remains inconclusive
Systematic reviews note that the clinical evidence base for honey’s metabolic effects includes dozens of trials but with heterogeneity in honey types, doses, populations and outcomes, and only a handful of studies specifically characterize Manuka honey in humans; safety trials have been conducted in healthy volunteers (UMF® 20+ safety study referenced), but promotional materials from honey sellers may overinterpret limited data or highlight single positive studies without full methodological context [2] [8] [6]. The net takeaway from the available reporting is that controlled human data specifically on dietary Manuka honey for lowering blood glucose in people with diabetes are sparse: there is a robust GI study in healthy subjects and several small or mixed trials suggesting modest metabolic effects from honey generally, but no large, definitive randomized trials focused on Manuka honey in diabetic patients are documented in the provided sources [1] [2] [3].